Edwards Lifesciences Corporation $EW Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 5.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 141,326 shares of the medical research company’s stock after buying an additional 7,214 shares during the quarter. HighTower Advisors LLC’s holdings in Edwards Lifesciences were worth $12,048,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Level Four Advisory Services LLC grew its position in shares of Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after acquiring an additional 119 shares in the last quarter. Colonial Trust Co SC raised its position in shares of Edwards Lifesciences by 0.4% during the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after acquiring an additional 120 shares in the last quarter. Evermay Wealth Management LLC raised its position in shares of Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 128 shares in the last quarter. Howard Capital Management Inc. lifted its stake in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after purchasing an additional 132 shares during the last quarter. Finally, Florida Trust Wealth Management Co boosted its holdings in Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after purchasing an additional 132 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.2%

Edwards Lifesciences stock opened at $85.93 on Monday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $49.48 billion, a price-to-earnings ratio of 45.71, a PEG ratio of 2.15 and a beta of 0.87. The firm has a 50-day moving average price of $81.42 and a two-hundred day moving average price of $82.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the previous year, the firm posted $0.64 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on EW. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Finally, BTIG Research raised their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.65.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 106,684 shares of company stock worth $8,811,739. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.